SCHEDULE: Vanguard Group Discloses 6.51% Stake in Maravai LifeSciences Holdings Inc.

The Vanguard Group has filed an amended Schedule 13G, reporting a beneficial ownership of 6.51% in Maravai LifeSciences Holdings Inc.'s common stock as of June 30, 2025.

Summary

• The Vanguard Group, an investment adviser based in Pennsylvania, reported beneficial ownership of 9,380,547 shares of Maravai LifeSciences Holdings Inc. common stock.
• This ownership represents 6.51% of the company's outstanding common stock.
• Vanguard holds sole dispositive power over 9,287,528 shares and shared dispositive power over 93,019 shares.
• Vanguard holds shared voting power over 50,788 shares and no sole voting power.
• The filing is an Amendment No. 4 to a previously filed Schedule 13G, indicating an update to their ownership position.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a significant institutional ownership stake. While not directly indicative of operational performance, a large, stable holding by a reputable firm like Vanguard is generally viewed as a neutral to slightly positive signal for long-term stability.

Positives

• The continued significant ownership by a major institutional investor like The Vanguard Group (6.51%) can be viewed as a vote of confidence in Maravai LifeSciences Holdings Inc.

Negatives

• This filing does not contain information that would typically be categorized as negatives regarding the company's performance or outlook.

Risks

• This filing, a Schedule 13G, primarily reports beneficial ownership and does not detail specific risks related to Maravai LifeSciences Holdings Inc.'s operations or financial health.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Maravai LifeSciences Holdings Inc.'s future performance or strategic outlook.

Management Comments

• The Vanguard Group certified that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing reflects a major institutional investor's continued stake in a life sciences company, which is common practice for large asset managers like Vanguard. It provides insight into the institutional ownership landscape of Maravai LifeSciences Holdings Inc. but does not offer broader industry trend analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
• Investment Professionals: Offers data points for analyzing institutional ownership trends and investor confidence in Maravai LifeSciences Holdings Inc.

Key Dates

Keywords

Maravai LifeSciences Holdings Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Equity Stake, Investment Adviser